UK health body rejects Novartis kidney cancer drug (Reuters)

Admin

Administrator
Staff member
Reuters - Novartis AG's cancer drug Afinitor has been rejected for patients with kidney cancer by Britain's health costs watchdog, which says it is too pricey for the country's taxpayer-funded National Health Service (NHS).

More...
 
Top